BlossomHill Therapeutics (NASDAQ:BLSM) General Counsel Purchases $35,200.00 in Stock

BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) General Counsel Vincent Paul Liptak acquired 2,200 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were bought at an average cost of $16.00 per share, with a total value of $35,200.00. Following the completion of the acquisition, the general counsel owned 111,412 shares in the company, valued at $1,782,592. This represents a 2.01% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink.

Vincent Paul Liptak also recently made the following trade(s):

• On Friday, August 7th, Vincent Paul Liptak purchased 2,500 shares of BlossomHill Therapeutics stock. The shares were purchased at an average cost of $15.80 per share, for a total transaction of $39,500.00.

BlossomHill Therapeutics Stock Down 1.7%

Shares of NASDAQ:BLSM opened at $16.24 on Thursday. BlossomHill Therapeutics, Inc. has a 1-year low of $15.25 and a 1-year high of $17.25.

About BlossomHill Therapeutics

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.